Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial-Reference-Cited by-同舟云学术

Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial

Published:2017-04-30 Issue:11 Volume:19 Page:1495-1503
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Komajda Michel¹,Isnard Richard¹,Cohen-Solal Alain²,Metra Marco³,Pieske Burkert⁴,Ponikowski Piotr⁵,Voors Adriaan A.⁶,Dominjon Fabienne⁷,Henon-Goburdhun Cécile⁷,Pannaux Matthieu⁸,Böhm Michael⁹,

Affiliation:

1. Department of Cardiology; University of Pierre and Marie Curie Paris VI, La Pitié-Salpêtrière Hospital; Paris France

2. UMR-S 942, Department of Cardiology; Paris Diderot University, Sorbonne Paris Centre, Lariboisière Hospital; Paris France

3. Department of Cardiology; University of Brescia; Brescia Italy

4. Department of Cardiology; Charité University; Berlin Germany

5. Department of Heart Diseases; Medical University and Centre for Heart Diseases, Military Hospital; Wrocław Poland

6. Department of Cardiology; University of Groningen; Groningen the Netherlands

7. Department of Cardiovascular Development, Institut de Recherches Internationales Servier (IRIS); Suresnes France

8. Department of Methodology and Data Valorisation; Institut de Recherches Internationales Servier (IRIS); Suresnes France

9. Department of Cardiology; Universitätskliniken des Saarlandes, Klinikum für Innere Medizin III; Homburg/Saar Germany

Funder

Les Laboratoires Servier (Suresnes, France)

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference20 articles.

1. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC);Ponikowski;Eur J Heart Fail,2016

2. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program;Castagno;J Am Coll Cardiol,2012

3. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve);Bohm;Eur J Heart Fail,2014

4. Heart rate lowering by specific and selective If current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease;DiFrancesco;Drugs,2004

5. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction;Manz;Cardiology,2003

Cited by 280 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Update in Heart Failure with Preserved Ejection Fraction;Current Heart Failure Reports;2024-09-03

2. Ivabradine Approved and Other Uses in Clinical Practice: A Systematic Review;Journal of Cardiovascular Pharmacology;2024-09

3. Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction;European Journal of Heart Failure;2024-08-31

4. Complexities of treating co‐morbidities in heart failure with preserved ejection fraction;ESC Heart Failure;2024-06-17

5. The Ideal Heart Rate for Heart Failure and Ejection Fraction > 40%: Both Myth and Magic?;Journal of Cardiac Failure;2024-06